Cargando…
Chemotherapy for hormone-resistant prostate cancer: Where are we today?
Significant progress has been achieved in chemotherapy for hormone-resistant prostate cancer (HRPC) in the last five years. Although the disease was long considered to be chemoresistant, docetaxel-based regimens in particular have been shown to both palliate symptoms and prolong survival in HRPC pat...
| Autores principales: | , |
|---|---|
| Formato: | Texto |
| Lenguaje: | English |
| Publicado: |
Medknow Publications
2007
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2721498/ https://www.ncbi.nlm.nih.gov/pubmed/19675765 http://dx.doi.org/10.4103/0970-1591.30269 |